Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
Benlong Yang,
Zhengkui Sun,
Quchang Ouyang,
Zhongsheng Tong,
Shu Wang,
Hongyuan Li,
Zhaofeng Niu,
Yiding Chen,
Lin-xiaoxi Ma,
Haoqi Wang,
Mu Tang,
Zheyu Hu,
Xueqiang Gao,
Xu Wang,
Fei Xie,
Qiao Cheng,
Yong Shen,
Cuizhi Geng,
Haibo Wang,
Jiong Wu
Affiliations
Benlong Yang
Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center
Zhengkui Sun
Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer
Quchang Ouyang
Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital
Zhongsheng Tong
Tianjin Medical University Cancer Institute & Hospital
Shu Wang
Peking University People’s Hospital
Hongyuan Li
The First Affiliated Hospital of Chongqing Medical University
Zhaofeng Niu
Yuncheng Women and Children Health Care Family Planning Service Center (Yuncheng Maternal and Child Health Hospital, Yuncheng Children’s Hospital)
Yiding Chen
The Second Affiliated Hospital, Zhejiang University School of Medicine
Lin-xiaoxi Ma
Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center
Haoqi Wang
Breast Center, Fourth Hospital of Hebei Medical University
Mu Tang
Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer
Zheyu Hu
Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital
Xueqiang Gao
The Affiliated Hospital of Qingdao University
Xu Wang
Tianjin Medical University Cancer Institute & Hospital
Fei Xie
Peking University People’s Hospital
Qiao Cheng
The First Affiliated Hospital of Chongqing Medical University
Yong Shen
The Second Affiliated Hospital, Zhejiang University School of Medicine
Cuizhi Geng
Breast Center, Fourth Hospital of Hebei Medical University
Haibo Wang
The Affiliated Hospital of Qingdao University
Jiong Wu
Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center
Abstract Background To investigate the treatment pattern, adverse events, and quality of life of Chinese patients treated with CDK4/6 inhibitors (CDK4/6i) for hormone receptor (HR)+/HER2- advanced breast cancer. Methods This multicenter cross-sectional survey enrolled patients with HR+/HER2- advanced breast cancer currently treated with CDK4/6i. The patients reported adverse events and quality of life during CDK4/6i treatment with a questionnaire and EORTC QLQ-BR23. Meanwhile, the oncologists collected the treatment information, adverse events and patient characteristics from medical record. Results The analysis included 1254 patients. Most patients received only one CDK4/6i, of which 38.92% received dalpiciclib, 35.81% received abemaciclib, 15.07% received palbociclib, and 0.47% received ribociclib, while 9.73% patients were treated with two CDK4/6i sequentially. The oncologists reported adverse events occurred in > 81.17% of patients, and most common AEs were leukopenia (63.30%) and neutropenia (58.73%). The most common symptomatic adverse events reported by the patients were fatigue (34.13%), alopecia (14.02%) and weakness (11.30%). The incidence of alopecia in patients receiving dalpiciclib was lower than in those receiving palbociclib (8.81% vs. 16.40%, P < 0.001) and abemaciclib (8.81% vs. 19.82%, P = 0.027). Regard to quality of life, breast symptom scores were lower in the palbociclib group than in the abemaciclib group (3.84 ± 8.57 vs. 5.70 ± 9.81, P = 0.047). Patient reported alopecia was associated with body image, systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss (all P < 0.001). Conclusions The safety profile of different CDK4/6i varies and has different impacts on patients’ quality of life, which needs more attention in clinical practice.
